Paolo Vigneri
Professore associato di ONCOLOGIA MEDICA [MED/06]
Email: vigneri.p@unict.it pvigneri@libero.it
Telefono: +39 095.312.389 int 6
Mobile: +39 095.378.1516
Fax: +39 095.7151.928
Orario di ricevimento: Mercoledì dalle 15:00 alle 17:00
1. Russo M, Malandrino P, Addario WP, Dardanoni G, Vigneri P, Pellegriti G, Squatrito S, Vigneri R.
Several Site-specific Cancers are Increased in the Volcanic Area in Sicily.
Anticancer Res. 2015; 35(7):3995-4001.
2. Recchia AG, Caruso N, Bossio S, Pellicanò M, De Stefano L, Franzese S, Palummo A, Abbadessa V, Lucia E, Gentile M, Vigna E, Caracciolo C, Agostino A, Galimberti S, Levato L, Stagno F, Molica S, Martino B, Vigneri P, Di Raimondo F, Morabito F.
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques.
PLoS One. 2015; 10(6):e0130360
3. Vigneri R, Malandrino P, Vigneri P
The changing epidemiology of thyroid cancer: why is incidence increasing?
Curr Opin Oncol. 2015; 26(1):185-92
4. Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F
Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.
PLoS One. 2014; 9 (7):e101848
5. Sciacca L, Cassarino MF, Genua M, Vigneri P, Giovanna Pennisi M, Malandrino P, Squatrito S, Pezzino V, Vigneri R
Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression.
J Cell Physiol. 2014; 229 (11):1817-21
6. Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Carcinogenesis. 2014; 35 (5):1132-43
7. Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G
Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.
Crit Rev Oncol Hematol. 2014; 90 (3):181-9
8. Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
FASEB J. 2014; 28 (3):1221-36
9. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.
Nutr Metab Cardiovasc Dis. 2013; 23 (9):808-15
10. Experts in Chronic Myeloid Leukemia
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Blood. 2013; 121 (22):4439-42
11. Frasca F, Vella V, Nicolosi ML, Messina RL, Gianì F, Lotta S, Vigneri P, Regalbuto C, Vigneri R
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
J Clin Endocrinol Metab. 2013; 98 (6):2502-12
12. Stella S, Tirrò E, Conte E, Stagno F, Di Raimondo F, Manzella L, Vigneri P
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Mol Cancer Ther. 2013; 12 (6):1085-98
13. Vigneri R, Vigneri P, Frittitta L
Basal insulin and cardiovascular and other outcomes.
N Engl J Med. 2012; 367 (18):1761-2
14. Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Ann Hematol. 2012; 92(2):179-83
15. Vicari L, Martinetti D, Buccheri S, Colarossi C, Aiello E, Stagno F, Villari L, Cavalli M, Di Raimondo F, Gulisano M, De Maria R, Vigneri P
Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocytemia and myelofibrosis patients.
Br J Haematol. 2012; 159 (2):237-40
16. Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F
Infliximab therapy in hematologic malignancies: handle with care.
Haematologica. 2012; 97 (8):e26-7
17.Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Hematol Oncol. 2012; 31(2):103-9
18. Stagno F, Vigneri P, Cupri A, Stella S, Di Raimondo F
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment.
Leuk Res. 2012; 36 (9):1208-9
19. Stagno F, Vigneri P, Di Raimondo F
Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.
Int J Hematol. 2012; 36 (9):1208-9
20.Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L
IRF5 promotes the proliferation of human thyroid cancer cells.
Mol Cancer. 2012; 11(1):21
21. Stagno F, Vigneri P, Di Raimondo F
Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
Leuk Res. 2012; 36 (7):803
22. Stagno F, Vigneri P, Cupri A, Vitale SR, Di Raimondo F
Diagnosis of blastic phase of chronic myeloid leukemia.
Acta Haematol. 2012; 127 (4):198
23. Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.
Acta Haematol. 2012; 127 (1):7-9
24. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianì F, Vigneri R, Frasca F
Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells.
Int J Cancer. 2012; 130 (10):2259-70
25.Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint.
Acta Haematol. 2011; 126 (4):205-10
26.Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Leuk Res. 2011; 35 (9):1164-9
27. Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Haematologica. 2011; 96 (10):1457-61
28.Maugeri-Saccà M, Vigneri P, De Maria R
Cancer stem cells and chemosensitivity.
Clin Cancer Res. 2011; 17 (15):4942-7
29. Breccia M, Stagno F, Gozzini A, Abruzzese E, Latagliata R, Rossi AR, Sorà F, Porrini R, Vigneri P, Trawinska M, Montefusco E, Sica S, Specchia G, Santini V, Alimena G
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
Am J Hematol. 2011; 86 (6):523-5
30. Preyer M, Vigneri P, Wang JY
Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
PLoS One. 2011; 6 (2):e17020
31. Stagno F, Vigneri P, Di Raimondo F
Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?
Lancet Oncol. 2011; 12 (2):118.
32. Stagno F, Vigneri P, Del Fabro V, Fidilio A, Spina P, Massimino M, Messina A, Di Raimondo F
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.
Acta Haematol. 2010; 124 (2):103-4.
33. Stagno F, Del Fabro V, Triolo A, Parrinello NL, Vigneri P, Di Raimondo F
Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia.
Acta Haematol. 2010; 123 (4):235-6
34. Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino A, Di Raimondo F
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Acta Oncol. 2010; 49 (4):506-8.
35. Breccia M, Stagno F, Vigneri P, Latagliata R, Cannella L, Del Fabro V, Di Raimondo F, Alimena G
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
Am J Hematol. 2010; 85 (5):375-7.
36. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
J Immunol. 2010; 184 (6):3260-8.
37. Stagno F, Vigneri P, Del Fabro V, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, Tirrò E, Buscarino C, Messina A, Di Raimondo F
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.
Acta Oncol. 2010; 49 (1):109-10.
38. Stagno F, Vigneri P, Stagno F, Vigneri P, Del Fabro V, Stella S, Berretta S, Massimino M, Tirrò E, Messina A, Di Raimondo F
Uncommon long-term survival in a patient with chronic myeloid leukemia.
Acta Oncol. 2009; 48 (8):1215-6.
39. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R
Diabetes and cancer.
Endocr Relat Cancer. 2009; 16 (4):1103-23.
40. Vigneri R, Frasca F, Sciacca L, Vigneri P, Frittitta L
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.
J Natl Cancer Inst. 2009; 101 (14):1030-1
41. Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Cupri A, Consoli C, Messina L, Tirrò E, Messina A, Di Raimondo F
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Leuk Res. 2009; 33 (9):e157-8.
42. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, Vigneri P, Nicotera P, Dyer MJ, Holyoake T, Salomoni P, Calabretta B
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
J Clin Invest. 2009; 119 (5):1109-23.
43. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P, Tell G, Frasca F
DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells.
Int J Cancer. 2009; 124 (11):2539-48.
44. Allan EK, Hamilton A, Hatziieremia S, Zhou P, Jørgensen HG, Vigneri P, Holyoake TL
Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells.
Leukemia. 2009; 23 (5):1006-8.
45. Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Messina A, Di Raimondo F
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Leuk Res. 2009; 33 (6):e17.
46. Stagno F, Stella S, Berretta S, Massimino M, Antolino A, Giustolisi R, Messina A, Di Raimondo F, Vigneri P
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Leuk Res. 2008; 32 (4):673-4.
47.Buffa P, Manzella L, Consoli ML, Messina A, Vigneri P
Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.
Proteins. 2007; 67 (1):1-11.
48. Vicari L, Eramo A, Manzella L, Malaguarnera L, Iannolo G, Gulisano M, De Maria R, Messina A, Vigneri P
The PU.1 transcription factor induces cyclin D2 expression in U937 cells.
Leukemia. 2006; 20 (12):2208-10.
49. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A and Vigneri P
Altered expression of c-IAP1, Survivin and Smac contributes to chemotherapy resistance in thyroid cancer cells.
Cancer Res. 2006; 66 (8):4263-72
50. Frasca F, Rustighi A, Malaguarnera R, Altamura S, Vigneri P, Del Sal G, Giancotti V, Pezzino V, Vigneri R, Manfioletti G
HMGA1 inhibits the function of p53 family members in thyroid cancer cells.
Cancer Res. 2006; 66 (6):2980-9
51. Aloisi A, Di Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, Gambacorti-Passerini C, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri P
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of Imatinib Mesylate and Leptomycin B.
Blood 2006; 107 (4):1591-98
52.Vigneri P, Frasca F, Sciacca L, Frittitta L, Vigneri R
Obesity and cancer.
Nutr Metab Cardiovasc Dis. 2006; 16 (1):1-7.
53.Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, Vigneri P, Aloisi A, Vigneri R and Frasca F
The p53-homologue p63 may promote thyroid cancer progression.
Endocr Relat Cancer 2005; 12 (4):953-971.
54.Frasca F, Vella V, Aloisi A, Mandarino A, Mazzon E, Vigneri R, Vigneri P
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 2003; 63 (18):5829-37.
55.Vella V, Zhu J, Frasca F, Li CY, Vigneri P, Vigneri R, Wang JY
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.
J. Biol. Chem. 2003; 278 (27):25151-7.
56.Frasca F, Vigneri P, Vella V, Vigneri R, Wang JY
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Oncogene. 2001; 20 (29):3845-56.
57. Vigneri P
BCR-ABL tyrosine kinase inhibitor may be safe and effective in myeloid blast crisis and acute lymphoblastic leukemia.
Cancer Treatment Reviews 2001; 2:152-154
58. Vigneri P, Wang JY
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
Nat. Med. 2001; (2):228-34.
59. Bunone G, Vigneri P, Mariani L, Butò S, Collini P, Pilotti S, Pierotti MA, Bongarzone I
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
Am. J. Pathol. 1999; 155 (6):1967-76.
60. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S
Iodide symporter gene expression in human thyroid tumors.
J. Clin. Endocrinol. Metab. 1998; 83 (7):2493-6.
61. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinico-pathological features.
Clin. Cancer Res. 1998; 4 (1):223-8.
62. Pilotti S, Collini P, Mariani L, Placucci M, Bongarzone I, Vigneri P, Cipriani S, Falcetta F, Miceli R, Pierotti MA, Rilke F
Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland.
Am. J. Surg. Pathol. 1997; 21 (12):1466-73.
63. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S, Belfiore A
Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma.
J. Clin. Endocrinol. Metab. 1997; 82 (3):735-8.
64. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID, Vigneri R
Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity.
Mol. Endocrinol. 1996; 10 (11):1318-26.
65. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA
Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma.
J. Clin. Endocrinol. Metab. 1996; 81 (5):2006-9.
Meccanismi della cancerogenesi nelle neoplasie solide ed ematologiche - Regolazione dei meccanismi che regolano la localizzazione intracellulare delle proteine - Individuazione e validazione di biomarcatori prognostici e predittivi di risposta ai farmaci biologici
PAROLE CHIAVE:
ALTERAZIONI GENETICHE E CANCRO - ANALISI MUTAZIONALE - BIOPSIA LIQUIDA - BRCA1 E BRCA2 - CARCINOMA MAMMARIO - LEUCEMIA MIELOIDE CRONICA - NEOPLASIE GINECOLOGICHE - NEXT GENERATION SEQUENCING - SARCOMI DEI TESSUTI MOLLI - SINDROMI MIELOPROLIFERATIVE CRONICHE
Coordinatore - Scuola di Specializzazione in Oncologia